Looking for a Growth Stock? 3 Reasons Why APi (APG) is a Solid Choice
APi (APG) possesses solid growth attributes, which could help it handily outperform the market.
APi (APG) Upgraded to Buy: What Does It Mean for the Stock?
APi (APG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are Business Services Stocks Lagging APi Group (APG) This Year?
Here is how APi (APG) and INTERTEK GP (IKTSY) have performed compared to their sector so far this year.
3 Stock Split Stocks to Buy in June
Key Points Forward stock splits usually indicate very strong fundamentals.
Is APi Group (APG) Stock Outpacing Its Business Services Peers This Year?
Here is how APi (APG) and Cap Gemini SA (CGEMY) have performed compared to their sector so far this year.
Apogee Therapeutics: APG808 Asthma Treatment May Overtake Dupixent In IL-4Rα Class
Apogee Therapeutics, Inc. achieved positive interim results from phase 1b study using APG808 for the treatment of patients with Asthma. Interim 16-week data from the phase 2 APEX study using APG777 for the treatment of patients with AD expected mid-2025. The global asthma treatment market size is projected to reach $35.93 billion by 2034.
3 Business Services Stocks to Watch in a Prospering Industry
The Zacks Business Services industry is poised to prosper with rising demand and growing technology adoption. CTAS, APG and BFAM are three stocks that appear well-poised to ride this demand strength.
APi (APG) Is Up 13.03% in One Week: What You Should Know
Does APi (APG) have what it takes to be a top stock pick for momentum investors? Let's find out.
APi Group Corporation (APG) Q1 2025 Earnings Call Transcript
APi Group Corporation (NYSE:APG ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Adam Fee – Vice President of Investor Relations Russ Becker – President and Chief Executive Officer David Jackola – Executive Vice President and Chief Financial Officer Conference Call Participants Andy Kaplowitz – Citigroup Tim Mulrooney – William Blair Jasper Bibb – Truist Securities Andy Wittmann – Baird Kathryn Thompson – Thompson Research Group Stephanie Moore – Jefferies Steve Tusa – JPMorgan Josh Chan – UBS Jack Cauchi – Barclays Operator Good morning, ladies and gentlemen, and welcome to APi Group's First Quarter 2025 Financial Results Conference Call. All participants are now in a listen-only mode until the question-and-answer session.
APi (APG) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for APi (APG) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
APi (APG) Q1 Earnings and Revenues Beat Estimates
APi (APG) came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.34 per share a year ago.
Apogee Therapeutics: Engineering Biologic Dominance
Apogee's strong financial position, with $731.1 million in cash, funds operations through Q1 2028, de-risking its ambitious pipeline development in inflammatory diseases. Significant R&D investments in lead IL-13 inhibitor APG777 and combination therapies reflect a strategic push for differentiated, best-in-class treatments in atopic dermatitis and asthma. Encouraging Phase 1 data for OX40L inhibitor APG990 supports its combination potential with APG777, promising infrequent dosing and broad efficacy in inflammatory diseases.
